Welcome to the 4th Neuroimmunology Drug Development Summit: Translating Key Technological, Cellular & Target Insights in Neuroinflammation into Clinically Effective Candidates
Since 2019, venture capitalists have been predicting a “golden era of neuroscience products” and successes of “radical new breakthrough therapies” in the notoriously challenging space.
Now, three years on, 2022 is hosting the neuroscience renaissance and pharma is doubling down to understand the neuropathological and neuroprotective role of neuroinflammation as the most promising opportunity to bring more targeted, precise and transformative therapies to neurodegenerative and neuropsychiatric diseases.
The 4th Neuroimmunology Drug Development Summit is the timely, industry-definitive forum providing actionable insights to target neuroimmunological mechanisms and advance drug development addressing neuroinflammation.
Download the full event guide here to view the full speaking faculty including Alector, Biogen, Lundbeck, Eisai and Elixiron Therapeutics.
Bringing together department and pipeline Heads across biopharma drug development, join over 100 colleagues to discuss the role of astrocytes, oligodendrocytes and peripheral immune cells; biomarker combinations to diagnose, stratify and design more successful clinical trials; and progress and potential of iPSC-derived organoids for more robust and translatable drug discovery and development research.
Want more content? With four additional workshops hosting detailed discussion and even more focused scientific insights, attend our workshop day to further your understanding into emerging areas of research expansion for neurological pipelines, including: the relationship with traumatic brain injury (TBI) and neuroinflammation, the gut-brain axis, and targeting genetic risk factors in various neurodegenerative, neuropsychiatric and behavioural impairments.
Industry Leading Speakers Include:
Reviews From the Neuroimmunology Community:
A unique opportunity to share and learn the latest developments and breakthrough innovations in the fast-emerging field of Neuroimmunology” - Michael Mingueneau, Director of Research, Biogen
“There are not a lot of meetings dedicated to drug development in neuroimmunology, making this summit a great opportunity to present new data and stay up-to-date with the field.” – Kuti Baruch, Head of R&D, ImmunoBrain Checkpoint
“Neuroinflammation is at the heart of Alzheimer’s disease and other neurodegenerative disorders. This conference will be an excellent forum for discussing causes and solutions to disease causing neuroiflammation.” – Stan Chamberlain, Chief Scientific Officer, T3D Therapeutics